A Dual-Target Shift in Metastatic Uveal Melanoma: Darovasertib + Crizotinib
In this article
The Darovasertib and Crizotinib Transformation in Metastatic Uveal Melanoma
News Release, 13 April 2026 · Clinical Trial: NCT05987332
Uveal melanoma is biologically entirely different from cutaneous melanoma and is resistant to treatment. According to the results announced on 13 April 2026 from Phase 2/3 OptimUM-02 , the combination of the PKC inhibitor Darovasertib and the cMET inhibitor Crizotinib more than doubled progression-free survival (PFS) in HLA-A*02:01-negative metastatic uveal melanoma, reducing the risk of disease progression by 58%.
Mechanism: Dual PKC and cMET Blockade
More than 90% of uveal melanomas carry GNAQ or GNA11 mutations, which keep the Protein Kinase C (PKC) pathway continuously active. Combination with Crizotinib's cMET inhibition puts a “double lock” on this aggressive cellular signalling network, breaking resistance.
Details of the OptimUM-02 Trial
This trial includes HLA-A*02:01-negative mUM patients who have not previously received systemic therapy (1st line). It was designed to address the limited efficacy of existing immunotherapies (Pembrolizumab, Ipi/Nivo) in this patient group.
- Control Group (ICT): In the group receiving standard chemotherapy or immunotherapy, the ORR was only 5.8%.
- Duration of Response (DOR): The median duration of response in the combination arm was 6.8 months.
- Overall Survival (OS): Although the data are not yet mature, an early trend towards improvement was reported in the combination arm.
Safety Profile and Adverse Events
Pooled safety data from the OptimUM-01 and 02 trials show that adverse events are generally manageable:
- Diarrhoea: 90.9% (Grade 3+ only 2.3%)
- Nausea: 79.5%
- Peripheral Oedema: 61.4%
- Acneiform Dermatitis: 43.2%
- Combination OS: 21.1 months
- Historical Controls: 10-12 months
- Lesion Reduction: Target-lesion shrinkage was observed in 85% of patients.
🎓 DROZDOGAN Academy — Scientific Commentary
UVEAL MELANOMA · PKC/CMET-TARGETED THERAPY · OPTIMUM-02
Unmet Need: HLA-A*02:01-Negative Patients
Tebentafusp's success was limited to HLA-A*02:01-positive patients. The OptimUM-02 results offer, for the first time, a “practice-changing” treatment option for the HLA-A*02:01-negative population, which represents more than half of patients with uveal melanoma. An ORR of 37% is a rare achievement in this challenging disease.
Shutting Down Signalling Pathways
GNAQ/11 mutations are like the engine of uveal melanoma. While Darovasertib holds the main gear of this engine (PKC), support from Crizotinib's cMET inhibition also closes the side routes that cancer cells use to survive. This dual blockade brings durable responses that monotherapies have so far failed to achieve.
Looking Ahead: A 2026 FDA Application
IDEAYA's planned New Drug Application (NDA) submission in the second half of 2026 will pave the way for this treatment to become standard care. The return of targeted therapies in the immunotherapy-resistant biology of mUM is a major gain for precision medicine.
Scientific References
- IDEAYA Biosciences. OptimUM-02 topline results: Darovasertib and crizotinib in first-line HLA-A*02:01-negative mUM. News release, April 13, 2026.
- McKean M, et al. First reported overall survival results from a phase 1/2 study of darovasertib plus crizotinib (OptimUM-01). SMR Congress 2025.
- ClinicalTrials.gov. IDE196 in combination with crizotinib as first-line therapy (NCT05987332). Updated February 2026.
This article was prepared in light of the latest trial phase results and clinical announcements from April 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.